1 month Madrigal Pharmaceuticals (NASDAQ:MDGL) Earns Buy Rating from HC WainwrightMarketBeat
HC Wainwright reiterated a “buy” rating and issued a $390.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Tuesday.
Nasdaq 100 · Pharmaceuticals · Science
X